JNM
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


The Journal of Nuclear Medicine Vol. 15 No. 10 848-855
© 1974 by Society of Nuclear Medicine
This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Krishnamurthy, G. T.
Right arrow Articles by Blahd, W. H.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Krishnamurthy, G. T.
Right arrow Articles by Blahd, W. H.

Clinical Comparison of the Kinetics of 99mTc-Labeled Polyphosphate and Diphosphonate

G. T. Krishnamurthy, Manuel Tubis, John S. Endow, V. Singhi, Carol F. Walsh and W. H. Blahd

VA Wadsworth Hospital Center, UCLA School of Medicine, and School of Pharmacy, University of Southern California, Los Angeles, California

Correspondence: For reprints contact: G. T. Krishnamurthy, Nuclear Medicine Service, VA Wadsworth Hospital Center, Los Angeles, Calif. 90073.

ABSTRACT

Kinetics of 99mTc-labeled polyphosphate and diphosphonate (disodium ethane-1-hydroxy-1, 1-diphosphonate) are studied and compared clinically in ten patients in a paired study. Four hours after injection, both agents show a biexponential type of blood clearance. The Exponent I represents bone uptake and the Exponent II, mainly the renal excretion. The clearance of diphosphonate is relatively faster than that of polyphosphate resulting in significantly lower blood background radioactivity. Both agents show identical plasma protein fraction binding and 4-hr urinary excretion. The kidneys are well visualized with both agents, consistently better with polyphosphate. The sensitivity for the detection of lesions is similar for both. At the end of 4 hr, 10% of the dose of 99mTc-polyphosphate is circulating in the blood, 33.3% is excreted in urine, and the remaining 56.3% is taken up by bone and other tissues. The corresponding values with 99mTc-diphosphonate are: 7.0% in blood, 33.8% in urine, and 59.2% in bone and other tissues. It is concluded that both 99mTc-labeled polyphosphate and diphosphonate are excellent skeletal-imaging agents and have equal sensitivity. No toxic reactions are noted with either agent.







HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
JOURNAL OF NUCLEAR MEDICINE TECHNOLOGY THE JOURNAL OF NUCLEAR MEDICINE
Copyright © 1974 by the Society of Nuclear Medicine.